Harry Lam, Ph.D. has been appointed head of manufacturing at KaloBios Pharmaceuticals, Inc. Dr. Lam has more than 28 years of experience in biopharma manufacturing, including 17 years at Genentech, where he ultimately served as global head of contract manufacturing operations, Commercial Drug Substance, for the Roche Group.
Dr. Lam most recently served as vice president and head of manufacturing for Shire Regenerative Medicine. He also held a variety of positions with increasing responsibility at Genentech related to manufacturing operations, science and technology, and fermentation operations. He served as global head of contract manufacturing operations, commercial drug substance, and senior director, Global Biologics Drug Substance Manufacturing Science & Technology.
David Pritchard, Kalobios' president and chief executive officer, said, "Dr. Lam’s experience in directing science and technology on a global basis for drug substance manufacturing will be especially pertinent to KaloBios as we continue to advance the development of our patient-targeted antibody therapeutics towards commercialization."